

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TEMPUS AI, INC.,
Petitioner,

v.

GUARDANT HEALTH INC.,
Patent Owner.

IPR2025-01435
Patent 10,793,916

**PATENT OWNER'S
UPDATED EXHIBIT LIST**

Updated Exhibit List

Exhibit No.	Description
2001	FMI Invalidity Chart Exhibit B-1
2002	FMI Invalidity Chart Exhibit D-1
2003	Excerpts from File History of U.S. Patent Application No. 15/669,779
2004	Excerpts from File History of U.S. Patent Application No. 16/601,168
2005	Excerpts from File History of U.S. Patent Application No. 16/672,267
2006	IPR2019-01400 - Patent Owner's Response
2007	IPR2022-01400 - Hearing Transcript
2008	IPR2022-01400 - Patent Owner's Surreply
2009	Excerpts from File History of U.S. Patent Application No. 15/828,099
2010	Excerpts from File History of U.S. Patent Application No. 16/593,633
2011	Excerpts from File History of U.S. Patent Application No. 16/277,724
2012	Patent Application Publication No. US20210098078A1
2013	Excerpts from File History of U.S. Patent Application No. 16/945,588
2014	Guardant360-Liquid-Specification-Sheet
2015	Tempus Proposed Claim Constructions, <i>Guardant Health, Inc., v. Tempus AI, Inc.</i> , Case 1:24-cv-00687

2016	<p>Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market – Leading Guardant 360 Test, Further Extending its Best-In-Class Performance.</p> <p>https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Introduces-Major-Smart-Liquid-Biopsy-Upgrade-to-Market-Leading-Guardant360-Test-Further-Extending-Its-Best-in-Class-Performance/default.aspx (last viewed on October 20, 2024)</p>
2017	<p>Guardant Health to Showcase New Data at ESMO 2022 Demonstrating Utility of its Portfolio of Blood Tests for Advanced – Stage Cancer Patients.</p> <p>https://investors.guardanthealth.com/press-releases/press-releases/2022/Guardant-Health-to-showcase-new-data-at-ESMO-2022-demonstrating-utility-of-its-portfolio-of-blood-tests-for-advanced-stage-cancer-patients/default.aspx (last viewed on October 20, 2024)</p>
2018	<p>FDA Approves First Liquid Biopsy Next-Generation Sequencing Companion Diagnostic Test. News Provided by U.S. Food and Drug Administration</p> <p>https://www.prnewswire.com/news-releases/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test-301108536.html (last viewed October 20, 2024)</p>
2019	<p>GOZILA Study Published in Nature Medicine Shows Patients with Advanced Cancer Who Receive Liquid Biopsy – Guided Treatment Using Guardant360 CDX Survive Twice as Long.</p> <p>https://investors.guardanthealth.com/press-releases/press-releases/2024/GOZILA-Study-Published-in-Nature-Medicine-Shows-Patients-With-Advanced-Cancer-Who-Receive-Liquid-Biopsy-Guided-Treatment-Using-Guardant360-CDx-Survive-Twice-as-Long/default.aspx (last viewed October 20, 2024)</p>
2020	<p>Guardant Health Named to TIME100 Most Influential Companies. https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Named-to-TIME100-Most-Influential-Companies/default.aspx (last viewed October 20, 2024)</p>

2021	Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation. https://investors.guardanthealth.com/press-releases/press-releases/2022/Guardant-Health-and-Foundation-Medicine-Reach-Settlement-in-Digital-Sequencing-Technology-Litigation/default.aspx (last viewed October 20, 2024)
2022	Guardant Health, Inc.’s First Amended Complaint, <i>Guardant Health, Inc., v. Tempus AI, Inc.</i> , Case 1:24-cv-00687
2023	Scott R. Kennedy, et al. “Detecting ultralow-frequency mutations by Duplex Sequencing
2024	Intentionally Left Blank
2025	Excerpts from Tempus AI, Inc.’s Preliminary Invalidity Contentions served on August 21, 2025, <i>Guardant Health, Inc., v. Tempus AI, Inc.</i> , Case 1:24-cv-00687
2026	Excerpts from Tempus AI, Inc.’s First Supplemental Preliminary Invalidity Contentions served on October 6, 2025, <i>Guardant Health, Inc., v. Tempus AI, Inc.</i> , Case 1:24-cv-00687

CERTIFICATE OF SERVICE

The undersigned certifies that the foregoing Patent Owner's Updated Exhibit List and accompanying Exhibits 2025-2026 were served on December 01, 2025, on the Petitioner at the electronic correspondence address of the Petitioner as follows:

James Glass
Margaret Shyr
QUINN EMANUEL URQUHART & SULLIVAN LLP
jimglass@quinnemanuel.com
margaretshyr@quinnemanuel.com
qu-tempus-IPRs@quinnemanuel.com

Respectfully submitted,

Date: December 01, 2025

/ Michael T. Rosato /
Michael T. Rosato, Lead Counsel
Reg. No. 52,182